Novartis stock trades steady as Q2 2026 results highlight solid specialty medicines growth

Novartis AG (ISIN CH0012005267) stock remains supported by improving profitability, with the Swiss pharma group reporting core operating income of $3.7 billion in Q2 2026, up 9% at constant currencies versus Q2 2025 according to its latest investor information as of 16 July 2026. This earnings trajectory sits alongside continued momentum in specialty medicines, which now account for the majority of group revenue.

Core operating income up 9 percent

According to the companys investor overview for Q2 2026, Novartis generated net sales of approximately $13.5 billion in the quarter, compared with around $13.0 billion in Q2 2025, implying mid single digit growth year on year. The reported core operating income of $3.7 billion for Q2 2026 represents a 9% increase at constant currencies relative to the prior-year period, with management attributing the improvement primarily to a richer mix of innovative therapies and disciplined cost control. In addition, the core operating income margin expanded by around 1 percentage point versus Q2 2025, highlighting ongoing efficiency gains across the focused portfolio.

Management has continued to emphasize that specialty medicines form the backbone of the groups strategy, and the Q2 2026 numbers underscore that focus. With net sales rising in immunology, oncology, and cardiovascular portfolios, the incremental expansion in margin demonstrates that new launches and lifecycle management of key brands support profitability beyond the top line. For investors, the quantified comparison of core operating income growth against the prior year provides a concrete signal that Novartis is translating its pipeline into earnings.

Revenue mix and earnings trajectory

Novartis investor disclosures for the first half of 2026 indicate that group net sales reached roughly $26.8 billion in H1 2026, up from about $25.8 billion in H1 2025, corresponding to around 4% growth at constant currencies. Over the same period, core operating income advanced from approximately $7.0 billion in H1 2025 to about $7.6 billion in H1 2026, an increase of close to 9% year on year in constant currency terms. This differential between revenue and earnings growth implies that the company is achieving operating leverage, with earnings expanding faster than sales as the product mix tilts toward higher margin therapies.

The earnings trajectory complements the broader restructuring story following prior portfolio streamlining moves. Novartis continues to focus on four core therapeutic pillars, and the H1 2026 metrics show that the strategy is generating incremental profitability. Investors frequently scrutinize whether large-cap pharma names can deliver earnings growth without resorting primarily to cost-cutting; the 9% core operating income increase versus about 4% net sales growth over the first half of 2026 offers evidence that mix and volume are meaningfully contributing.

Cash generation remains an important part of the investment thesis as well. Over the first half of 2026, Novartis reported operating cash flow of roughly $6.0 billion, compared with around $5.6 billion in H1 2025. Although the increase is more modest than the earnings growth, it reinforces the view that the earnings expansion is supported by real cash conversion rather than purely accounting effects. For income-oriented shareholders, the combination of rising operating income and cash flow provides a foundation for continued dividend capacity within the constraints of the Swiss corporate framework.

Cosentyx drives immunology revenue

Within immunology, Cosentyx has remained a key revenue driver for Novartis, reflecting its established position in indications such as psoriasis, psoriatic arthritis, and ankylosing spondylitis. In Q2 2026, Cosentyx net sales are estimated at roughly $1.4 billion, compared with about $1.3 billion in Q2 2025, corresponding to approximately 8% year on year growth at constant currencies. Over H1 2026, Cosentyx sales rose toward $2.7 billion versus around $2.5 billion in H1 2025, highlighting that the brand continues to grow despite competitive pressure from other biologics.

This mid single to high single digit growth in an established franchise underscores the durability of Novartis immunology platform. While the absolute growth rate may not be in the double digits typical of early pipeline launches, an 8% revenue increase on a multibillion-dollar base still adds meaningful incremental earnings. Because Cosentyx enjoys relatively attractive margins, its growth supports the overall expansion in core operating income observed in Q2 and H1 2026. Investors often watch for signs that large, mature brands are stabilizing or declining; in the case of Cosentyx, the evidence from the latest period points to ongoing volume and market-share resilience.

Beyond Cosentyx, Novartis immunology and cardiovascular portfolios include newer assets that are ramping. These products provide upside to revenue trajectories but also require upfront investment in commercial infrastructure and medical education. The fact that core operating income is rising faster than net sales suggests that these investments are being paced effectively, allowing the company to absorb launch expenses while maintaining growth in profitability. For market participants assessing Novartis against global peers, the balance between mature brand durability and new asset expansion is a critical factor.

Pipeline, guidance, and portfolio focus

Novartis pipeline remains diversified across oncology, immunology, neuroscience, and cardiovascular, with several late-stage programs positioned to potentially support revenue after key patent expiries. Investor materials for Q2 2026 highlight that the company continues to allocate research and development spending at a level consistent with prior years, with R&D expenses in H1 2026 estimated at around $4.5 billion compared with roughly $4.4 billion in H1 2025. This slight increase indicates a sustained commitment to innovation, even as management takes a disciplined approach to portfolio prioritization.

The company guidance for full year 2026, as presented in its recent investor communications, points to mid single digit net sales growth at constant currencies and high single digit growth in core operating income. This implies that management expects the operational leverage seen in H1 2026 to continue through the remainder of the year. For investors, the alignment between actual H1 performance and full-year guidance is an important confidence factor: net sales growth of about 4% and core operating income growth near 9% in H1 indicate that the company is tracking close to its targets.

Portfolio focus also plays a role in the investment story. Novartis has previously executed spin-offs and divestments to streamline its business, leaving a more concentrated group profile centered on higher growth, higher margin therapeutic areas. The performance metrics in H1 2026 suggest that this focus is contributing to earnings resilience despite sector-wide pricing and regulatory pressures. While guidance is not a guarantee, the quantified expectations provide an anchor for consensus models and frame investor debates about valuation and relative performance versus global large-cap pharma benchmarks.

Key therapies support Novartis strategy

One representative product within the Novartis portfolio is Cosentyx, a flagship biologic in immunology that illustrates how individual therapies support the broader corporate strategy. With Q2 2026 net sales around $1.4 billion and an estimated 8% year on year increase at constant currencies, Cosentyx demonstrates the role of established specialty medicines in providing stable, scalable revenue streams. The therapy addresses chronic inflammatory conditions with a safety and efficacy profile that has allowed Novartis to build a strong presence in dermatology and rheumatology markets.

From an investor perspective, the performance of Cosentyx and similar key brands is a tangible indicator of franchise health. If large products such as Cosentyx can sustain mid single to high single digit growth on a multibillion-dollar base, they offer a buffer against lifecycle risks and pricing challenges. At the same time, their cash flows help fund the development and launch of new assets in the pipeline, contributing to the virtuous cycle that underpins the Novartis investment case.

Novartis stock and market context

Novartis stock is primarily listed on SIX Swiss Exchange in Zurich under the symbol NVS, and it also trades in the United States via an American Depositary Receipt on the New York Stock Exchange. As of 16 July 2026, Novartis ADRs on the NYSE were quoted around $102 per share, placing the stock in the upper portion of its 52-week trading range between approximately $85 and $105. At that price level, the companys market capitalization is estimated near $215 billion, reflecting its status as one of the largest global pharmaceutical groups.

For investors, the proximity of the share price to the upper end of the recent range offers a concrete chart reference: Novartis stock is trading closer to its 52-week high than its low, in line with the improving profitability and revenue growth metrics reported for H1 2026. While the stock price incorporates numerous factors beyond the companys control, including broader market sentiment and sector rotation, the combination of mid single digit sales growth, high single digit operating income growth, and resilient cash generation provides fundamental context for the current valuation.